Case Presentation:

This is a 91 year old female with past medical history of basal cell skin cancer who presented and reported what was initially a solitary nodule on her scalp which rapidly progressed to multiple nodules over her head and torso. The lesions were deep red to purple and very painful. Her dermatologist had performed a shave biopsy which showed “cutaneous anaplastic malignancy of unclear origin.” PET/CT showed multiple areas of hypermetabolic skin thickening and hypermetabolic lymph nodes in groin and retroperitoneum. She was referred to a cutaneous oncologist. At the time of presentation she reported rapid progression of the size and number of nodules over 2 weeks. Punch biopsy, CT of the head, and tumor markers were done at the initial visit. Head CT showed multiple subcutaneous nodules over the scalp as well as possible right intraorbital mass. Tumor markers including beta HCG, alpha fetoprotein, CA‐125, and CA19‐9 were all unremarkable. Punch biopsy showed myeloid sarcoma (MS). On follow up she was noted to have further progression of the lesions‐ with lesions now covering most of her body including the mucous membranes. She was admitted to the hospital for multiple issues including newly diagnosed myeloid sarcoma, acute kidney injury, pneumonia, and urinary tract infection. The MS was treated during her admission with azacitidine and dexamethasone. She had only minimal improvement in her skin lesions after treatment. Her hospital course was complicated by tumor lysis syndrome, renal failure, and disseminated intravascular coagulation. Given her overall poor performance status and minimal response to treatment, the patient and her family requested hospice referral.

Discussion:

Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute leukemia first described in 1811. MS has also been referred to as “chloroma” because of its characteristic green color caused by the presence of myeloperoxidase. MS has been reported in 2.5‐9.1% of patients with AML. MS may appear concomitant with, following, or in rare cases prior to the onset of systemic bone marrow leukemia. There are limited data on prognostic relevance of MS. Five year survival rates for patients with MS range from 20‐30% similar to rates for AML. MS presenting without AML will nearly always progress to AML without treatment. Time to progression from MS to AML ranges from 5 months to one year. Standard AML treatment regimens are recommended for isolated MS. The rate of progression to AML in patients receiving localized treatment is 88‐100% compared with 42% in patients receiving systemic AML chemotherapy. Radiotherapy is often used however the data does not show clear benefit.

Conclusions:

Hospitalists are increasingly involved in the care of oncology patients. This case highlights a rare presentation of a common hematologic malignancy, This case serves to remind hospitalists who routinely care for oncology patients that cancer diagnoses and presentations are varied and not always clear at time of presentation.